A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome

Trial Profile

A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Bemcentinib (Primary) ; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors BerGenBio
  • Most Recent Events

    • 17 Jun 2018 Results assessing single cell signaling pharmacodynamics and clonal evolution presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 Results (n=35) measuring plasma protein biomarker levels presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results assessing identification of predictive and pharmacodynamic biomarkers from NCT02488408, NCT03184571, NCT03184558 NCT02872259, NCT02424617 and NCT02922777 trials presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top